Literature DB >> 25082467

The Ontario Drug Policy Research Network: bridging the gap between Research and Drug Policy.

Sobia Khan1, Julia E Moore2, Tara Gomes3, Ximena Camacho4, Judy Tran2, Glenn McAuley5, David N Juurlink6, Michael Paterson4, Andreas Laupacis7, Muhammad M Mamdani8.   

Abstract

Policymakers have cited several barriers to using evidence in policy decisions, including lack of research relevance and timeliness. In recent years, several reports have focused on the successes and challenges of researcher-policymaker collaborations, a form of policy engagement intended to help overcome barriers to the use of research evidence in policymaking. Although these reports often demonstrate an increase in research relevance, rarely do they provide concrete methods of enhancing research timeliness, which is surprising given policymakers' expressed need to receive "rapid-response" research. Additionally, the impact of researcher-policymaker collaborations is not well-discussed. In this paper, we aim to describe the collaboration between the Ontario Drug Policy Research Network (ODPRN) and its policymaker partner, the Ontario Public Drug Program (OPDP), with a particular focus on the ODPRN's research methodology and unique rapid-response approach for policy engagement. This approach is illustrated through a specific case example regarding drug funding policies for pulmonary arterial hypertension. Moreover, we discuss the impact of the ODPRN's research on pharmaceutical policy and lessons learned throughout the ODPRN and OPDP's five-year partnership. The described experiences will be valuable to those seeking to enhance evidence uptake in policymaking for immediate policy needs.
Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Evidence-informed policy; Pharmaceutical policy; Researcher–policymaker collaboration

Mesh:

Substances:

Year:  2014        PMID: 25082467     DOI: 10.1016/j.healthpol.2014.06.007

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  4 in total

1.  Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.

Authors:  Mina Tadrous; Simon Greaves; Diana Martins; Muhammad M Mamdani; David N Juurlink; Tara Gomes
Journal:  CMAJ Open       Date:  2018-03-14

2.  Facilitating factors and barriers to malaria research utilization for policy development in Malawi.

Authors:  Chikondi A Mwendera; Christiaan de Jager; Herbert Longwe; Kamija Phiri; Charles Hongoro; Clifford M Mutero
Journal:  Malar J       Date:  2016-10-19       Impact factor: 2.979

3.  Individual and institutional capacity-building for evidence-informed health policy-making in Iran: a mix of local and global evidence.

Authors:  Leila Doshmangir; Hakimeh Mostafavi; Masoud Behzadifar; Bahareh Yazdizadeh; Haniye Sadat Sajadi; Edris Hasanpoor; Mahdi Mahdavi; Reza Majdzadeh
Journal:  Health Res Policy Syst       Date:  2022-02-12

4.  Development of a framework to improve the utilisation of malaria research for policy development in Malawi.

Authors:  Chikondi Mwendera; Christiaan de Jager; Herbert Longwe; Charles Hongoro; Kamija Phiri; Clifford M Mutero
Journal:  Health Res Policy Syst       Date:  2017-11-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.